Potential New Treatment for Non-CF Bronchiectasis

Trial Objectives

---

Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic, progressive lung disease that leads to damage to the structures of the lung, chronic cough and shortness of breath. Currently, no treatments are specifically approved for this condition, and management focuses on reducing exacerbations and addressing symptoms. Researchers are investigating a new investigational inhaled drug called ensifentrine that may be able to help treat NCFBE.

In this study, volunteers will be randomly assigned to receive either ensifentrine or a placebo (a medication containing no active ingredient). Researchers will evaluate if the experimental medication can help improve symptoms and reduce exacerbations.

During clinic visits, volunteers will receive physical examinations, lung function tests and provide information on symptoms they have experienced.